Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). GRAIL, Inc. is a commercial stage healthcare company.
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that GRAIL, Inc. (NASDAQ: GRAL) Misled Investors Regarding its Business Operations.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL’s NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial’s end had been reduced. When the true details entered the market, the lawsuit claims that investors suffered damages.
